AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22704099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial sling surgery
Number of subjects: 655
Study 22704099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior urinary incontinence surgery
Number of subjects: 655
Study 22704099 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal status
Number of subjects: 655
Study 22704099 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative urge index
Number of subjects: 655
Study 20453177 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped instruction of a behavioral intervention (swaddling, side positioning, white noise, jiggling, sucking)
Number of subjects: 51
Study 20453177 — intervention group
Group type: COMPARATOR
Intervention: Control group (videotape with instructions for normal newborn care)
Number of subjects: 51
Study 20453177 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped instruction of a behavioral intervention
Number of subjects: 51
Study 20453177 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Stress Index
Number of subjects: 51
Study 18503600 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 18503600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16001905 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound feedback, verbal, and palpatory feedback (Group 3)
Number of subjects: 48
Study 16001905 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and palpatory feedback (Group 2)
Number of subjects: 48
Study 16001905 — intervention group
Group type: COMPARATOR
Intervention: Minimal verbal feedback (Group 1)
Number of subjects: 48
Study 16001905 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound feedback (Group 3)
Number of subjects: 48
Study 16001905 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention testing for all groups
Number of subjects: 48
Study 12458389 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtraction-only images
Number of subjects: 88
Study 12458389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined images
Number of subjects: 88
Study 12458389 — intervention group
Group type: COMPARATOR
Intervention: Sestamibi-only images
Number of subjects: 88
Study 10219444 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosurgery using trichloroacetic acid (TCA)
Number of subjects: 0
Study 10219444 — intervention group
Group type: COMPARATOR
Intervention: Nontreated side (control)
Number of subjects: 0
Study 7553109 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser photorefractive keratectomy (PRK) with a 193nm ArF excimer laser (ExciMed, Summit) for myopic corrections of between -6.20 D and -11.90 D.
Number of subjects: 176
Study 1971599 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol
Number of subjects: 9
Study 1971599 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 9
Study 1971599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7426232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stesolid (diazepam in propylene glycol)
Number of subjects: 200
Study 7426232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stesolid MR (diazepam in Cremophor EL)
Number of subjects: 200
Study 7426232 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazemuls (diazepam dissolved in oil and emulsified in water)
Number of subjects: 200
Study 30595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (twice-weekly group classes and once-weekly home practice focused on Iyengar-based yoga techniques)
Number of subjects: 56
Study 30595143 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonspecific muscle stretching and strengthening program)
Number of subjects: 56
Study 30595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group
Number of subjects: 56
Study 30595143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 28836934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-Sirolimus (21 patients)
Number of subjects: 44
Study 28836934 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus-Mycophenolate (23 patients)
Number of subjects: 44
Study 26986743 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-dependent loudness balancing
Number of subjects: 15
Study 26986743 — intervention group
Group type: COMPARATOR
Intervention: Broadband balancing
Number of subjects: 15
Study 24890683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 964
Study 24890683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 964
Study 22374636 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated with 2-min bouts of light-intensity walking every 20 min
Number of subjects: 19
Study 22374636 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated with 2-min bouts of moderate-intensity walking every 20 min
Number of subjects: 19
Study 22374636 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 19
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (added to Risperidone)
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0
Study 21183132 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 17122092 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP (4x12.5 microg administered intravenously in a pulsatile fashion hourly between 2200 and 0100)
Number of subjects: 8
Study 17122092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15826328 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D ultrasound scanning
Number of subjects: 44
Study 15826328 — intervention group
Group type: COMPARATOR
Intervention: 2D ultrasound scanning (control group)
Number of subjects: 44
Study 12391470 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 52
Study 12391470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 52
Study 12391470 — intervention group
Group type: COMPARATOR
Intervention: Control (Carbamazepine)
Number of subjects: 52
Study 10447050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine i.v. bolus (0.69 or 0.75 mg x kg(‐1)) under hyperbaric/hyperoxic conditions (HBO: 2.5 bar or 0.25 MPa)
Number of subjects: 2
Study 10447050 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine i.v. bolus (0.69 or 0.75 mg x kg(‐1)) under normobaric conditions (NB: 1 bar or 0.1 MPa, air)
Number of subjects: 2
Study 7604949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 7
Study 7604949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate or beclomethasone dipropionate
Number of subjects: 7
Study 7604949 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (Fluticasone propionate or beclomethasone dipropionate)
Number of subjects: 7
Study 2270529 — intervention group
Group type: COMPARATOR
Intervention: Platelet aggregation (PA) measurements before treatment and yearly during a 3-year period
Number of subjects: 93
Study 2270529 — intervention group
Group type: COMPARATOR
Intervention: Platelet aggregation (PA) tests
Number of subjects: 93
Study 7370358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus ascending success feedback (AS)
Number of subjects: 0
Study 7370358 — intervention group
Group type: COMPARATOR
Intervention: Bogus equally distributed success feedback (EDS)
Number of subjects: 0
Study 7370358 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NF)
Number of subjects: 0
Study 31506029 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling based on Bandura's self-efficacy theory (6 sessions of 90 minutes each)
Number of subjects: 96
Study 31506029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 96
Study 30287669 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT plus standard medical care (SMC)
Number of subjects: 0
Study 30287669 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 0
Study 30287669 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT plus SMC
Number of subjects: 0
Study 30287669 — intervention group
Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 0
Study 26733609 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT) - four 4-minute intervals at 85% to 95% of peak heart rate, 3 times a week for 12 weeks
Number of subjects: 51
Study 26733609 — intervention group
Group type: COMPARATOR
Intervention: Control group - continuing regular exercise habits
Number of subjects: 51
Study 26733609 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 51
Study 24648802 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002 (50 mg/day)
Number of subjects: 60
Study 24648802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23048011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (triphasic estradiol and norethisterone acetate for women with intact uterus; 2 mg estradiol for women with hysterectomy)
Number of subjects: 1006
Study 23048011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 1006
Study 23048011 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1006
Study 20509942 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (160/4.5 microg)
Number of subjects: 17
Study 20509942 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol (4.5 microg)
Number of subjects: 17
Study 20509942 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (2 x 100 microg)
Number of subjects: 17
Study 20509942 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 18763287 — intervention group
Group type: EXPERIMENTAL
Intervention: C14‐urea breath test (C14‐UBT)
Number of subjects: 244
Study 18763287 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology test
Number of subjects: 244
Study 18763287 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori IgG antibodies
Number of subjects: 244
Study 18763287 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative H pylori serology test
Number of subjects: 244
Study 18763287 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive H pylori titres
Number of subjects: 244
Study 16249890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIg) at 0.75 g/kg/day for 5 days
Number of subjects: 6
Study 16249890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporin A (CsA) at 5 mg/kg/day for 5 days
Number of subjects: 6
Study 16249890 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (Control)
Number of subjects: 6
Study 12717008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure (10,000 lx for 6 min fixed gaze and 5,000-9,000 lx for 6 min free gaze)
Number of subjects: 21
Study 12717008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 21
Study 10762507 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidentified bright objects (UBOs) on MRI
Number of subjects: 38
Study 10762507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding UBOs as a diagnostic criterion
Number of subjects: 38
Study 10762507 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between two pediatric neuroradiologists
Number of subjects: 38
Study 8941008 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 386
Study 8941008 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (standard therapy)
Number of subjects: 386
Study 1351737 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (n = 8)
Number of subjects: 20
Study 1351737 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium (n = 12)
Number of subjects: 20
Study 6373094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 1.0 g or 0.5 g daily on a bid regimen (30 mg/kg mean daily dose)
Number of subjects: 157
Study 6373094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 1.0 g or 0.5 g daily on a qid regimen (29 mg/kg mean daily dose)
Number of subjects: 157
Study 30564933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncokompas
Number of subjects: 205
Study 29125702 — intervention group
Group type: EXPERIMENTAL
Intervention: PTL101 containing 10 mg CBD
Number of subjects: 0
Study 29125702 — intervention group
Group type: EXPERIMENTAL
Intervention: PTL101 containing 100 mg CBD
Number of subjects: 0
Study 29125702 — intervention group
Group type: COMPARATOR
Intervention: Sativex oromucosal spray (reference product)
Number of subjects: 0
Study 1596595 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 10
Study 1596595 — intervention group
Group type: COMPARATOR
Intervention: Naftidrofuryl
Number of subjects: 10
Study 1596595 — intervention group
Group type: COMPARATOR
Intervention: Other classes of drugs (vasodilators, antiplatelet drugs, anticoagulants, prostaglandins)
Number of subjects: 10
Study 1596595 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping smoking
Number of subjects: 10
Study 1596595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising regularly
Number of subjects: 10
Study 22541408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 μg/d)
Number of subjects: 962
Study 22541408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962
Study 20508978 — intervention group
Group type: COMPARATOR
Intervention: Community-wide intervention alone (tribe A)
Number of subjects: 205
Study 20508978 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide intervention with family component (tribes B and C)
Number of subjects: 205
Study 20508978 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide intervention (tribe A)
Number of subjects: 205
Study 20508978 — intervention group
Group type: EXPERIMENTAL
Intervention: All tribes
Number of subjects: 205
Study 18251036 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin-based CS-avoidance regimen (n = 16)
Number of subjects: 32
Study 18251036 — intervention group
Group type: COMPARATOR
Intervention: Long-term CS-based regimen with no antibody induction (control group; n = 16)
Number of subjects: 32
Study 15511603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 0.25 mg dexamethasone suppression test (LD-DST)
Number of subjects: 118
Study 15511603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal vasoconstrictor assay (DVVA)
Number of subjects: 118
Study 15511603 — intervention group
Group type: EXPERIMENTAL
Intervention: BclI GG genotype association
Number of subjects: 118
Study 15511603 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPS scores correlation
Number of subjects: 118
Study 15511603 — intervention group
Group type: EXPERIMENTAL
Intervention: N363S and BclI GR polymorphisms
Number of subjects: 118
Study 15511603 — intervention group
Group type: COMPARATOR
Intervention: Basal plasma cortisol levels
Number of subjects: 118
Study 12200975 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP/BPBM/GTR
Number of subjects: 18
Study 12200975 — intervention group
Group type: COMPARATOR
Intervention: GTR
Number of subjects: 18
Study 10630494 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLA) 250 mg
Number of subjects: 16
Study 10630494 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 16
Study 8941814 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel crowns
Number of subjects: 0
Study 8941814 — intervention group
Group type: COMPARATOR
Intervention: Multisurface amalgam restorations
Number of subjects: 0
Study 1934204 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories, 100 mg q8hr for five doses
Number of subjects: 50
Study 1934204 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 50
Study 6130197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cl2MDP 1600 mg/day orally
Number of subjects: 34
Study 6130197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28617715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-pause group (n = 9; 3 sets of 6 repetitions with 80% of 1-repetition maximum (1RM) and 2-minute rest intervals)
Number of subjects: 18
Study 28617715 — intervention group
Group type: COMPARATOR
Intervention: Traditional multiple-set group (n = 9; 3 sets of 6 repetitions with 80% of 1-repetition maximum (1RM) and 2-minute rest intervals)
Number of subjects: 18
Study 28617715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-pause group
Number of subjects: 18
Study 28617715 — intervention group
Group type: COMPARATOR
Intervention: Traditional multiple-set group
Number of subjects: 18
Study 29624362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 530
Study 26946419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ologen implant (OLO)
Number of subjects: 40
Study 26946419 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C (MMC)
Number of subjects: 40
Study 23823710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity resistance training
Number of subjects: 46
Study 23823710 — intervention group
Group type: COMPARATOR
Intervention: Low-velocity resistance training
Number of subjects: 46
Study 21953301 — intervention group
Group type: EXPERIMENTAL
Intervention: Madenci hand massage technique + splint
Number of subjects: 84
Study 21953301 — intervention group
Group type: COMPARATOR
Intervention: Splint only
Number of subjects: 84
Study 18952699 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based screening study for chronic kidney disease (CKD)
Number of subjects: 6311
Study 21753727 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch)
Number of subjects: 302
Study 21753727 — intervention group
Group type: COMPARATOR
Intervention: Control (capsaicin 0.04% wt/wt)
Number of subjects: 302
Study 16240703 — intervention group
Group type: COMPARATOR
Intervention: Bimosiamose disodium 30 mg/kg
Number of subjects: 0
Study 16240703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12091327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine prophylaxis administered to 13 patients for 1 to 60 days (mean, 15 days) before immunosuppressive treatment and continued for 0.5 to 24 months (mean, 7 months) after initiation of immunosuppression.
Number of subjects: 18
Study 12091327 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients) who were HBV carriers treated for hematological malignancies without lamivudine.
Number of subjects: 18
Study 10337288 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel used nightly for 2 weeks
Number of subjects: 29
Study 9005783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 124
Study 9005783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Ofloxacin
Number of subjects: 124
Study 2011615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 40
Study 2011615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7138749 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg labetalol
Number of subjects: 6
Study 7138749 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg labetalol
Number of subjects: 6
Study 7138749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30328648 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 80
Study 30328648 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (0.25 mg/kg)
Number of subjects: 80
Study 26316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sit-to-stand training
Number of subjects: 50
Study 26316551 — intervention group
Group type: COMPARATOR
Intervention: Sit-to-stand training with symmetrical foot position (Control)
Number of subjects: 50
Study 25704750 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP015K (10, 25, 60, 100 mg twice daily; 50 mg once daily)
Number of subjects: 124
Study 25704750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 24304715 — intervention group
Group type: EXPERIMENTAL
Intervention: läuft. program (multicomponent school-based program including pedometers, competitions, educational lessons, and parental involvement)
Number of subjects: 100
Study 24304715 — intervention group
Group type: EXPERIMENTAL
Intervention: läuft. program
Number of subjects: 100
Study 20650784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested preparation (orally disintegrating tablets of pentoxyverine citrate)
Number of subjects: 20
Study 20650784 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (orally disintegrating tablets of pentoxyverine citrate)
Number of subjects: 20
Study 18087205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 641
Study 15728039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 52
Study 15728039 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 52
Study 12762636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 3 capsules (570 mg of iodine)
Number of subjects: 36
Study 12762636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 1 ml of Lipiodol UF (480 mg of iodine)
Number of subjects: 36
Study 12762636 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of Lipiodol
Number of subjects: 36
Study 12762636 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Lipiodol
Number of subjects: 36